Skip Navigation

European Journal of Heart Failure 2004 6(3):359-363; doi:10.1016/j.ejheart.2004.01.008
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bettencourt, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bettencourt, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society of Cardiology

NT-proBNP and BNP: biomarkers for heart failure management

Paulo Bettencourt*

Departamento de Medicina Interna, Serviço de Medicina B – Hospital S. João, Faculdade de Medicina da Universidade do Porto, Unidade I&D Cardiovascular do Porto Porto, Portugal

* Serviço de Medicina B, Hospital S. João – Piso 4, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal. Tel.: +351-22-8327463; Fax: +351-22-5089788 E-mail address: pbettfer{at}esoterica.pt


   Abstract
Top
 Abstract
1. Introduction
 2. NT-proBNP, BNP and...
 3. NT-proBNP, BNP and...
 4. Correlation of NT-proBNP...
 5. Association between changes...
 6. NT-proBNP-guided therapy
 References
 
Guidelines for the pharmacological treatment of heart failure (HF) are based on results from large clinical trials demonstrating benefit. State of the art pharmacological management of HF assumes that target doses should be the same as those used in trials. Thus equal doses are recommended for all in practical guidelines, but this strategy might not fit individual needs. NT-proBNP and BNP emerged as potential biomarkers of clinical interest in HF management. NT-proBNP and BNP are related to HF severity and to clinical status. NT-proBNP and BNP are strongly associated with prognosis across the whole spectrum of HF patients. A pilot study has shown that NT-proBNP-guided therapy is associated with improved outcome in HF. Although at present there are still few data to make firm recommendations on the use of NT-proBNP or BNP levels as biomarkers for HF management, future studies will provide further insight on this issue.

Key Words: Heart failure • Natriuretic peptides • Prognosis • Mortality

Received November 21, 2003; Accepted January 15, 2004


   1. Introduction
Top
 Abstract
 1. Introduction
2. NT-proBNP, BNP and...
 3. NT-proBNP, BNP and...
 4. Correlation of NT-proBNP...
 5. Association between changes...
 6. NT-proBNP-guided therapy
 References
 
Results from clinical trials on heart failure (HF) have led to major improvements in patient care. The pharmacological treatment of HF is based on the results of these trials and consists mainly of ACE-inhibitors, beta-blockers and aldosterone antagonists plus diuretics [1–5]. State of the art pharmacological management of HF assumes that target doses of these drugs should be the same as in the trials that dictate their use [6–8]. However, this strategy, based on equal doses for all, as recommended in guidelines, might not fit individual needs. Should patients with different co-morbidities and different body mass indexes receive the same treatment? Should patients who are doing well on standard therapy have their treatment intensified based on poor prognostic indexes? These questions suggest that individualization of HF therapy might be necessary [9].

Measurement of brain natriuretic peptide (BNP) and the amino terminal portion of the pro-hormone (NT-proBNP) is already available for clinical use in many European countries and in the United States. European health authorities have approved BNP and NT-proBNP testing to assist clinicians in the diagnosis of HF [10–15]. The prognostic value of BNP and NT-proBNP in HF patients is also established [16–20]. Individualization of HF therapy based on NT-proBNP has also been suggested [21].

As in other diseases, in order to be clinically useful, a biomarker has to be sensitive and specific for the disease process, and its measurement has to be standardized and easy to perform. Additionally, the test should demonstrate biological validity, for instance, BNP levels must be related to the clinical status and/or prognosis of patients with HF; and/or variations in BNP levels should be related to changes in clinical status and in prognosis. If all of the above are fulfilled then optimization of BNP levels through changes in therapy should translate into improved clinical outcome.


   2. NT-proBNP, BNP and clinical status in HF patients
Top
 Abstract
 1. Introduction
 2. NT-proBNP, BNP and...
3. NT-proBNP, BNP and...
 4. Correlation of NT-proBNP...
 5. Association between changes...
 6. NT-proBNP-guided therapy
 References
 
There is a large body of evidence that NT-proBNP and BNP levels correlate well with the severity of HF [16,22–24]. The more severe the HF the higher the BNP and NT-proBNP levels. Even among patients with mild HF, NT-proBNP levels, but not BNP levels, are significantly higher in class II compared to class I patients. The suggested pathophysiological explanation for this observation is related to the different clearance mechanism for BNP and NT-proBNP [25].

Clinical status in HF has been traditionally assessed by functional impairment. The most widely used instrument to accomplish this goal is the New York Heart Association (NYHA) classification. NYHA classification gives crude but clinically relevant information. Other ways to evaluate clinical status include quality of life scales and exercise performance. The 6-min walk test, although not routinely used, provides independent prognostic information [26]. Patients with better exercise performance (evaluated by the 6-min walk test or by peak VO2 consumption test) have lower levels of BNP [27]. In a sample of HF patients in which the whole spectrum of NYHA classes was represented, an inverse correlation between BNP and the distance walked in 6 min has been reported. In this study, within the same NYHA class, patients who walked the shortest distance in 6 min had the highest BNP levels. These results suggest that BNP levels add information to the NYHA classification in the evaluation of clinical status in heart failure.


   3. NT-proBNP, BNP and prognosis in HF
Top
 Abstract
 1. Introduction
 2. NT-proBNP, BNP and...
 3. NT-proBNP, BNP and...
4. Correlation of NT-proBNP...
 5. Association between changes...
 6. NT-proBNP-guided therapy
 References
 
The identification of HF patients at high risk of cardiovascular events is critical to select those who will benefit from more aggressive intervention and referral to specialized services.

NT-proBNP and BNP concentrations are higher in patients with HF who have the most severe symptoms and ventricular dysfunction and the worst prognosis [28,29]. Although BNP correlates with peak VO2 and symptoms and the severity of LV dysfunction, its prognostic value is independent and superior to NYHA class, age, ejection fraction, VO2 and prior myocardial infarction [20,30].

Recent studies have included patients on beta-blockers and spironolactone, as well as angiotensin II receptor blockers [31–33]. NT-proBNP and BNP were consistently shown to have independent prognostic value.

In a recent study evaluating ‘traditional’ indexes as well as NT-proBNP in patients with severe HF, only NT-proBNP predicted death or urgent heart transplantation, supporting its potential role in selecting patients for heart transplantation.


   4. Correlation of NT-proBNP and BNP levels with changes in clinical status
Top
 Abstract
 1. Introduction
 2. NT-proBNP, BNP and...
 3. NT-proBNP, BNP and...
 4. Correlation of NT-proBNP...
5. Association between changes...
 6. NT-proBNP-guided therapy
 References
 
For NT-proBNP and BNP to be useful in clinical practice they should mirror modifications in clinical status. In a small sample of outpatients, only changes in BNP levels were associated with changes in NYHA class [22]. Patients with improving NYHA class had decreasing levels of BNP, while patients with clinical deterioration had increasing BNP levels. The results of this small study suggest that the direction of BNP change parallels changes in clinical status. In hospitalized patients admitted with HF decompensation clinical improvement is associated with a significant decrease in BNP levels [34,35]. Data on NT-proBNP are similar. In a recent study, we observed and followed for 6 months, 176 patients hospitalized due to decompensated HF. NT-proBNP was measured at admission and at the day of discharge. Twenty patients died in the hospital. Plasma levels of NT-proBNP (mean±S.D.) measured at admission in these patients were higher than in patients discharged alive (28 345.4±21 653.7 pg/ml vs. 14 463.8±24 859.5 pg/ml, P<0.001). NT-proBNP levels in patients who improved by at least two NYHA classes during hospitalization (n=85) decreased significantly more (30.1±49.1% vs. 3.2±75.7%, P=0.01) than in the other patients (n=71).


   5. Association between changes in NT-proBNP and BNP and prognosis
Top
 Abstract
 1. Introduction
 2. NT-proBNP, BNP and...
 3. NT-proBNP, BNP and...
 4. Correlation of NT-proBNP...
 5. Association between changes...
6. NT-proBNP-guided therapy
 References
 
Probably even more important is the association between changes in NT-proBNP and BNP and modification of prognosis. In other words, optimizing levels of natriuretic peptides through changes in therapy might translate into improved clinical outcomes.

ACE inhibitors improve outcome in heart failure [1,2]. ACE-inhibitors can reduce BNP levels in patients with HF and even attain normal levels in patients with mild to moderate HF [36–38].

The effect of beta-blockers on BNP levels is less well known. We observed a decrease in patients with mild to moderate HF 8–12 months after the initiation of beta-blockers [39]. Others have reported similar findings [18]. Recent data showed that 3 months after initiation of beta-blockers in HF, there was no change or mild elevations in NT-proBNP levels, but at 6 and 12 months there was a significant decrease in NT-proBNP levels [40].

Results from the ValHeFT study showed that patients in the valsartan arm had a significant decrease in BNP levels while patients in the placebo arm had an increase in BNP [33]. In the Rales Trial, patients in the treatment arm had significant decreases in BNP levels throughout the study period, while patients in the placebo arm had no significant changes in BNP levels. All these data demonstrate that drugs that modify prognosis in HF lead to a decrease in NT-proBNP and BNP levels.

The association between changes in NT-proBNP and BNP levels and prognosis may also be of interest. In patients with mild to moderate heart failure, we found that those with increasing BNP levels during an 8–12-month period had a significantly worse prognosis than those with decreasing levels [39]. Furthermore, we found that patients with baseline BNP level above median and increasing BNP levels had the worst prognosis, while those with low and decreasing BNP levels had the best prognosis. In other words, serial evaluations of BNP can help identify high and low risk patients (Fig. 1).


Figure 1
View larger version (8K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 (a) Kaplan–Meier estimates of cumulative survival of patients with initial BNP below ({blacksquare} {blacksquare} {blacksquare} {blacksquare}) and above (——) the median of the distribution. Median initial BNP=260.4 pg/ml. P (log-rank)=0.03. (b) Kaplan–Meier estimates of cumulative survival of patients whose BNP level decreased ({blacksquare} {blacksquare} {blacksquare} {blacksquare}, n=56) or increased (——, n=28). P (log-rank)=0.04. (c) Kaplan–Meier estimates of cumulative survival of patients with initial BNP level below the median and decreasing ({blacksquare} {blacksquare} {blacksquare} {blacksquare}, n=22), initial BNP below the median and increasing (——, n=20), initial BNP above the median and decreasing (– –, n=34), and initial BNP above the median and increasing (——, n=8). P (log-rank)<0.001. (Adapted from Bettencourt P. Int J Cardiol 2003).

 
Results from the ValHeFT study confirm this hypothesis. In ValHeFT, BNP was measured at baseline and after 4 months [33]. Patients with decreasing BNP levels had a significantly better prognosis than those with increasing BNP during this period.

Results from hospitalized patients point in the same direction. We observed that BNP levels at hospital discharge are associated with outcome [34]. Patients with increasing BNP levels during hospitalization had a worse prognosis than those with decreasing levels. BNP decreased more among patients without adverse events than in those with an adverse event during follow-up. The direction and the magnitude of BNP change during hospitalization of HF patients might help clinicians in planning hospital discharge. We found similar results with NT-proBNP in a group of 156 patients hospitalized due to HF decompensation. Patients with increasing NT-proBNP levels during hospitalization had significantly more re-hospitalizations or death than patients with decreasing NT-proBNP levels (Fig. 2). Multivariate Cox regression analysis showed that the percent decrease in the levels of NT-proBNP during hospitalization was the most powerful predictor of outcome (Table 1).


Figure 2
View larger version (10K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 Kaplan–Meier estimates of cumulative hospitalization-free survival of patients whose NT-proBNP level decreased (n=117) or increased (n=39) during hospitalization. P (log-rank)<0.0001.

 


View this table:
[in this window]
[in a new window]

  		Table 1 Adjusted hazard ratios (HR) and their 95% confidence intervals (95% CI) obtained in multivariate Cox regression analysis (dependent variable: hospitalization-free survival) in 156 patients discharged after an index hospitalization due to decompensated heart failure

 

   6. NT-proBNP-guided therapy
Top
 Abstract
 1. Introduction
 2. NT-proBNP, BNP and...
 3. NT-proBNP, BNP and...
 4. Correlation of NT-proBNP...
 5. Association between changes...
 6. NT-proBNP-guided therapy
References
 
These results suggest that monitoring HF therapy through NT-proBNP or BNP levels could be of value. A pilot study has evaluated NT-proBNP-guided therapy [40]. Patients were randomly allocated to receive either symptom-guided treatment or treatment based on NT-proBNP levels. The group assigned to NT-proBNP based therapy received higher doses of ACE-inhibitors and diuretics. After 10 months, fewer events occurred in the group of patients treated according to NT-proBNP levels. A larger study is now ongoing in patients taking beta-blockers and spironolactone as well as diuretics and ACE-inhibitors. This study will hopefully provide evidence on whether NT-proBNP can be used as a surrogate end-point in the monitoring of HF treatment.


   References
Top
 Abstract
 1. Introduction
 2. NT-proBNP, BNP and...
 3. NT-proBNP, BNP and...
 4. Correlation of NT-proBNP...
 5. Association between changes...
 6. NT-proBNP-guided therapy
 References
 

  1. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med (1992) 327(10):685–691.[Abstract]
  2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med (1987) 316(23):1429–1435.[Abstract]
  3. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med (1996) 334(21):1349–1355.[Abstract/Free Full Text]
  4. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. J Am Med Assoc (2000) 283(10):1295–1302.[Abstract/Free Full Text]
  5. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med (1999) 341:709–717.[Abstract/Free Full Text]
  6. Remme WJ, Swedberg K, European Society of Cardiology. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002;4(1):11–22.
  7. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation (2001) 104(24):2996–3007.[Free Full Text]
  8. Packer M, Cohn JN, editors. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83 Suppl:1A–38A.
  9. Stevenson L.W. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail (1999) 1(3):251–257.[Free Full Text]
  10. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet (1998) 351:9–13.[CrossRef][Web of Science][Medline]
  11. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 350:1347–1351.
  12. Dicstein K. Natriuretic peptides in detection of heart failure. Lancet (1997) 351:3–4.[CrossRef][Web of Science]
  13. Maisel A.M., Krishnaswamy P., Nowak R., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 347:161–167. for the BNP Study Investigators.[Abstract/Free Full Text]
  14. Bettencourt P., Ferreira A., Dias P., Castro A., Martins L., Cerqueira-Gomes M. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology (2000) 93(1–2):19–25.[CrossRef][Web of Science][Medline]
  15. Lainchbury J.G., Campbell E., Framptom C.M., Yandle T.G., Nicholls M.G., Richards A.M. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol (2003) 42:728–735.[Abstract/Free Full Text]
  16. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure; prognostic role of plasma brain natriuretic peptide concentrations in patients with chronic symptomatic left ventricular dysfunction. Circulation (1997) 96:509–516.[Abstract/Free Full Text]
  17. Tsutamoto T., Wada A., Maeda K., et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J (1999) 20(24):1799–1807.[Abstract/Free Full Text]
  18. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol (2001) 38:436–442.[Abstract/Free Full Text]
  19. Bettencourt P., Ferreira A., Dias P., et al. Predictors of prognosis in mild to moderate heart failure. J Card Fail (2000) 6:306–313.[CrossRef][Web of Science][Medline]
  20. Gardner R.S., Ozalo F., Murday A.J., Robb S.D., McDonagh T.A. N terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J (2003) 24:1735–1743.[Abstract/Free Full Text]
  21. Richards A.M., Lainchbury J.G., Nicholls M.G., Troughton R.W., Yandle T.G. BNP in hormone-guided treatment of heart failure. Trends Endocrinol Metab (2002) 13(4):151–155.[CrossRef][Web of Science][Medline]
  22. Lee S.C., Stevens T.L., Sandberg S.M., et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail (2002) 8:149–154.[CrossRef][Web of Science][Medline]
  23. Koglin J., Pehlivanli S., Schwaiblmair M., Vogeser M., Cremer P., von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol (2001) 38:1934–1941.[Abstract/Free Full Text]
  24. Stein B.C., Levin R.I. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J (1998) 914–923.
  25. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (1997) 47:287–296.[CrossRef][Medline]
  26. Bittner V., Weiner D.H., Yusuf S., et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. J Am Med Assoc (1993) 270(14):1702–1707.[Abstract/Free Full Text]
  27. Jourdain P., Funck F., Bellorini M., et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail (2003) 5(2):155–160.[Abstract/Free Full Text]
  28. Kruger S., Graft J., Kunz D., Stickel T., Hanrath P., Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol (2002) 40:718–722.[Abstract/Free Full Text]
  29. Richards A.M., Doughty R., Nicholls M.G., et al. Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol (2001) 37(7):1781–1787.[Abstract/Free Full Text]
  30. Koglin J., Pehliuanli S., Schaiblmair M., Vogeser M., Cremer P., von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol (2001) 38:1934–1941.[Abstract/Free Full Text]
  31. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation (2002) 105:2392–2397.[Abstract/Free Full Text]
  32. Tsutamoto T., Wada A., Maeda K., et al. Effect of spironolactone on plama brain natriuretic peptide in patients with congestive heart failure. J Am Coll Cardiol (2001) 37:1228–1233.[Abstract/Free Full Text]
  33. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2002) 106:2454–2458.[Abstract/Free Full Text]
  34. Bettencourt P., Ferreira S., Azevedo A., Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med (2002) 113:215–219.[CrossRef][Web of Science][Medline]
  35. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol (2001) 37:386–391.[Abstract/Free Full Text]
  36. Yoshimura M., Mizuno Y., Nakayama M., et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med (2002) 112:716–720.[CrossRef][Web of Science][Medline]
  37. Ferreira A., Bettencourt P., Dias P., et al. Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clin Sci (Lond) (2001) 1:100–105.
  38. Murdock D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored vs. empirical therapy. Am Heart J (1999) 138:1126–1132.[CrossRef][Web of Science][Medline]
  39. Bettencourt P., Friões F., Azevedo A., et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol (2004) 93:45–48.[CrossRef][Web of Science][Medline]
  40. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide concentrations. Lancet (2000) 355:1126–1130.[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
L. Frankenstein, C. Zugck, M. Nelles, D. Schellberg, H. A. Katus, and B. A. Remppis
The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders
Eur J Heart Fail, December 1, 2009; 11(12): 1189 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
L. A. Bockeria, O. L. Bockeria, and U. A. Kolesnikova
eComment: Re: Brain natriuretic peptide a predictive marker in cardiac surgery
Interactive CardioVascular and Thoracic Surgery, October 1, 2009; 9(4): 666 - 666.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
Y. Wang, Y. Zhou, L. Meng, X. Lu, N. Ou, and X. Li
Inflammatory Mediators in Chinese Patients With Congestive Heart Failure
J. Clin. Pharmacol., May 1, 2009; 49(5): 591 - 599.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Frankenstein, A. Remppis, M. Nelles, B. Schaelling, D. Schellberg, H. Katus, and C. Zugck
Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status
Eur. Heart J., November 1, 2008; 29(21): 2634 - 2640.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
I. Ben-Dor, M. Haim, E. Rechavia, D. Murninkas, D. Harell, A. Porter, Z. Iakobishvili, A. Battler, and D. Hasdai
Serum NT-proBNP Concentrations in the Early Phase Do Not Predict the Severity of Systolic or Diastolic Left Ventricular Dysfunction Among Patients With ST-Elevation Acute Myocardial Infarction
Angiology, January 1, 2007; 57(6): 686 - 693.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Clerico, F. A. Recchia, C. Passino, and M. Emdin
Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Jefic, J. W. Lee, D. Jefic, R. T. Savoy-Moore, and H. S. Rosman
Utility of B-Type Natriuretic Peptide and N-terminal Pro B-Type Natriuretic Peptide in Evaluation of Respiratory Failure in Critically Ill Patients
Chest, July 1, 2005; 128(1): 288 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
V. Verdiani, C. Nozzoli, F. Bacci, A. Cecchin, M. S. Rutili, S. Paladini, and I. Olivotto
Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit
Eur J Heart Fail, June 1, 2005; 7(4): 566 - 571.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bettencourt, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bettencourt, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?